glp-1 receptor agonists and cardiovascular outcome trials an update Cardiovascular, mortality, kidney outcomes with in patients with type 2 diabetes: a systematic review and meta-analysis of randomised Efficacy of GLP‐1 receptor agonists

Vancouver: iData Research

Send questions or comments to [email protected]

In conclusion, tirzepatide increased blood pressure and sympathetic activity in hypertensive rats without cardiac protection, highlighting context-dependent cardiovascular actions

Amylin-Targeting Drugs May Be the Next Wave in Obesity and Diabetes Treatment While GLP-1 medications currently dominate the weight loss and diabetes markets, several major pharmaceutical companies in addition to Roche and Zealand are now working to develop drugs that mimic amylin

Sometimes we have a person who's living with a higher BMI and that medication might make the difference for that patient receiving bariatric surgery or not, she said

Together these studies suggest that GLP-1-RA exert comparable results with little evidence for species-specific differences